A9102
AH13205
≥98% (HPLC), oil
别名:
trans-2-(4-(1-Hydroxyhexyl)phenyl-5-oxocyclopentaneheptanoic acid
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C24H36O4
化学文摘社编号:
分子量:
388.54
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
assay
≥98% (HPLC)
form
oil
color
pale yellow
solubility
DMSO: >10 mg/mL
originator
GlaxoSmithKline
storage temp.
−20°C
SMILES string
CCCCCC(O)c1ccc(cc1)[C@H]2CCC(=O)[C@@H]2CCCCCCC(O)=O
InChI
1S/C24H36O4/c1-2-3-6-10-22(25)19-14-12-18(13-15-19)20-16-17-23(26)21(20)9-7-4-5-8-11-24(27)28/h12-15,20-22,25H,2-11,16-17H2,1H3,(H,27,28)/t20-,21-,22?/m1/s1
InChI key
XMQKDOCUWFCMEJ-JAZPPYFYSA-N
General description
AH13205 is EP2 prostanoid receptor agonist. There are five types of prostanoid receptors, which are classified based on sensitivity to the five naturally-occuring prostanoid ligand. The EP type of receptor is further divided into four subgroups – EP1, EP2, EP3 and EP4. EP2 activation results in vascular, bronchial and reproductive smooth muscle relaxation.
Biochem/physiol Actions
AH13205 is a selective, low potency agonist for the EP2 receptor. AH13205 has been shown to compete with Prostaglandin E2 (PGE2) for binding, resulting in the displacement of PGE2 binding.
Features and Benefits
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Hirohisa Ohmiya et al.
Journal of the American Chemical Society, 128(6), 1886-1889 (2006-02-09)
A cobalt-diamine complex catalyzes the cross-coupling reactions of primary and secondary alkyl halides with aryl Grignard reagents. It is confirmed that oxidative addition of alkyl halide to cobalt proceeds via a radical process. Optically pure Ueno-Stork halo acetals undergo diastereoselective
M M Teixeira et al.
British journal of pharmacology, 121(1), 77-82 (1997-05-01)
1. Prostanoids induce a wide range of biological actions which are mediated by specific membrane-bound receptors. We have recently shown that the E-type prostaglandins, PGE1 and PGE2, effectively inhibit eosinophil aggregation induced by platelet-activating factor (PAF). In an attempt to
A Wheeldon et al.
British journal of pharmacology, 108(4), 1051-1054 (1993-04-01)
1. We have evaluated the effects of various prostanoid agonists on the release of leukotriene B4 (LTB4) and superoxide anions (O2-) from human neutrophils stimulated with opsonized zymosan (OZ) and formyl-methionyl-leucyl-phenylalanine (FMLP), respectively. 2. Prostaglandin E2 (PGE2) and PGD2 inhibited